Slide 1: Second Quarter 2021 – Financial Results
SECOND QUARTER 2021 – FINANCIAL RESULTS August 2021 Exhibit 99.2
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical fa
Slide 3: Recent Highlights
RECENT HIGHLIGHTS Successful completion of the validation study for the Preecludia™ rule-out test for preeclampsia Achieved the primary endpoint of the study protocol Demonstrated strong performance and a high NPV in line with target in a broad use population Proceeding toward publication in peer-re
Slide 4: Innovation Pipeline Update
INNOVATION PIPELINE UPDATE
Slide 5: Preecludia Rule-Out Test for Preeclampsia
PREECLUDIA™ RULE-OUT TEST FOR PREECLAMPSIA Test developed with >3,700 patient samples, targeting NPV >95% PRE-VALIDATION DATA SET N = 356 enrolled subjects** Demonstrated commercial laboratory systems readiness Performance consistent with verification study NPV >97%, sensitivity >87%, with prevalenc
Slide 6: Drug Programs
DRUG PROGRAMS Drug/Device Combination Products and Drug Delivery Systems ORAL SYSTEMIC DELIVERY OF BIOTHERAPEUTICS PGN-0B1: adalimumab + OBDS GMP drug substance batch produced PGN-OB2: GLP-1 agonist + OBDS LOCALIZED DRUG DELIVERY FOR GI DISORDERS PGN-600: tofacitinib + DDS PGN-001: adalimumab + DDS
Slide 7: Gastrointestinal Health - Diagnostics
GASTROINTESTINAL HEALTH - DIAGNOSTICS Ingestible GI diagnostic platforms DISCOVERY AND DIAGNOSTICS IN MULTIPLE GI DISEASES Recover and preserve: Microbial and cellular samples Multi-omics opportunities LEAD INDICATION = SIBO: >100 MILLION PATIENT VISITS/YEAR No capsule recovery required Multiple flu
Slide 8: Single-Molecule Detection Platform
SINGLE-MOLECULE DETECTION PLATFORM Q4 2020 Made critical advancement by finalizing probe pool design and testing Q3 2020 Achieved development milestone demonstrating potential to “quantify” fetal fraction 1H 2022 Anticipated validation exit QUALITY RESULTS Maintain premium clinical value and reliabi
Slide 9: Near-Term Potential Catalysts
PREECLUDIA publication & partnership ongoing efforts Q3 2021 PREECLUDIA validation data SINGLE-MOLECULE NIPT verification study WOMEN’S HEALTH ORAL BIOTHERAPEUTICS RSS clinical proof of concept study OBDS Initiate first clinical PK/PD studies PGN-OB2 pre-IND meeting with FDA GI/PHARMA topline clinic
Slide 10: Operating Expenses
OPERATING EXPENSES
Slide 11: Opex Reductions
OPEX REDUCTIONS Secured $97 million in OPEX1 annual run rate reductions (66% of target)2 to be realized in the second half of 2021 Expecting additional $50 million in OPEX annual run rate reduction by end of Q4 20212 Monthly expense run rate reducing from $15 million in 1H’21 to <$7 million by end o
Slide 12: Progenity
progenity’